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http://dx.doi.org/10.1016/j.stemcr.2017.01.003SUMMARYSecreted factors are a key component of stem cell niche and their dysregulation compromises stem cell function. Legumain is a secreted
cysteine protease involved in diverse biological processes. Here, we demonstrate that legumain regulates lineage commitment of human
bone marrow stromal cells and that its expression level and cellular localization are altered in postmenopausal osteoporotic patients. As
shown by genetic and pharmacological manipulation, legumain inhibited osteoblast (OB) differentiation and in vivo bone formation
through degradation of the bone matrix protein fibronectin. In addition, genetic ablation or pharmacological inhibition of legumain
activity led to precocious OB differentiation and increased vertebralmineralization in zebrafish. Finally, we show that localized increased
expression of legumain in bone marrow adipocytes was inversely correlated with adjacent trabecular bone mass in a cohort of patients
with postmenopausal osteoporosis. Our data suggest that altered proteolytic activity of legumain in the bonemicroenvironment contrib-
utes to decreased bone mass in postmenopausal osteoporosis.INTRODUCTION
Human bone marrow stromal cells (hBMSCs) are non-he-
matopoietic multipotent cells capable of differentiation
into mesodermal cell types such as osteoblasts (OBs) and
adipocytes (ADs) (Abdallah andKassem, 2008). It is increas-
ingly recognized that secreted factors have an important
role inmediating hBMSC function to activelymaintain ho-
meostasis of skeletal tissue. In addition, secreted proteins
mediate the observed therapeutic effects of hBMSCs on
enhancing regeneration of skeletal (Hernigou et al.,
2005), cardiac (Hare et al., 2009), dermal (Bey et al.,
2010), and neural (Yamout et al., 2010) tissues. Character-
izing the functions of proteins secreted by hBMSCs is a
pre-requisite for understanding the mechanisms of their
therapeutic effects and their role in tissue homeostasis in
normal and disease states.
We recently reported a profile of hBMSC-secreted factors
at different stages of ex vivo OB differentiation using a
quantitative proteomic analysis based on stable isotope la-
beling by amino acids in cell culture (Kristensen et al.,
2012). Among the differentially regulated proteins duringStem Cell R
This is an open access article under the COB differentiation, we identified legumain as a secreted
protein that has not been previously implicated in hBMSC
biology.
Legumain (also known as asparaginyl endopeptidase,
AEP), encoded by the LGMN gene, is a broadly expressed
lysosomal cysteine protease that is secreted as inactive pro-
legumain (56 kDa) and processed into enzymatically active
46 and 36 kDa forms, as well as a 17 kDa enzymatically
inactive C-terminal fragment. Legumain directly regulates
diverse physiological and pathological processes by remod-
eling tissue-specific targets (e.g., extracellular matrix [ECM]
components, enzymes, receptors) (Chen et al., 2001; Clerin
et al., 2008; Deryugina and Quigley, 2006; Ewald et al.,
2008, 2011; Liu et al., 2003; Manoury et al., 1998; Mattock
et al., 2010;Miller et al., 2011;Morita et al., 2007; Papaspyr-
idonos et al., 2006; Sepulveda et al., 2009; Solberg et al.,
2015). In addition, legumain indirectly contributes to
atherosclerotic plaque instability through activation of
cathepsin L in the arterial ECM (Clerin et al., 2008; Kita-
moto et al., 2007; Mattock et al., 2010; Papaspyridonos
et al., 2006). Surprisingly, the non-enzymatic 17 kDa
C-terminal fragment is also biologically active and inhibitseports j Vol. 8 j 373–386 j February 14, 2017 j ª 2017 The Authors. 373
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
osteoclast differentiation through binding to an uncharac-
terized receptor (Choi et al., 1999, 2001).
Here we report the role of legumain in regulating the dif-
ferentiation fate of hBMSCs. Using cell-based and in vivo
studies we show that legumain inhibited OB differentia-
tion through degradation of fibronectin. During develop-
ment, legumain-deficient zebrafish exhibited precocious
bone formation and mineralization. Finally, abnormal
expression and cellular localization of legumain was
observed in bone biopsies obtained from patients with
postmenopausal osteoporosis. Together, the present study
reveals role of legumain in determining the differentiation
fate of BMSCs thereby regulating bone formation.RESULTS
Legumain Expression and Activity Are Regulated
during hBMSC Differentiation In Vitro and In Vivo
To assess cellular localization and regulation of legumain
(LGMN) expression during OB differentiation under
normal physiological conditions, we first performed histo-
logical analysis of adult human iliac crest bone biopsies. Le-
gumain immunoreactivity was present in osteoprogenitors
near bone-forming surfaces which included perivascular,
canopy, and reversal cells (Figure 1A) (Delaisse, 2014; Kris-
tensen et al., 2014).We did not detect immunoreactivity in
mature OBs, osteocytes, or osteoclasts (Figure 1A). Legu-
main mRNA showed a similar expression pattern (Fig-
ure 1B). Next, we examined legumain expression and activ-
ity during ex vivo OB differentiation of hBMSCs. LGMN
mRNA expression increased (Figure 1C) and the mature
LGMN protein (36 kDa) accumulated (Figures 1D and 1E)
during the early commitment phase (days 1–6) and were
downregulated during the late maturation phase (days 6–
18) of OB differentiation. Correspondingly, legumain enzy-
matic activity was reduced in differentiatedOBs (Figure 1F).
In contrast, LGMN mRNA expression and protein levels
were increased during AD differentiation of hBMSCs (Fig-
ures 1G–1I).Legumain Deficiency Enhances OB Differentiation
and Impairs AD Differentiation of hBMSCs
We employed lentiviral transduction to generate hBMSC
lines with stable expression of LGMN shRNA (shLGMN)
or a non-targeting control (shCtrl). shLGMN significantly
reduced legumain mRNA, protein, and activity levels (Fig-
ures 2A–2C). In addition, LGMN knockdown reduced
hBMSC proliferation (Figure S1A). After 6 days under oste-
ogenic culture conditions, LGMN knockdown did not alter
alkaline phosphatase (ALP) activity (Figure 2D), or expres-
sion of the early OB commitment markers ALP and
collagen 1 alpha 1 chain (Col1a1), but significantly upregu-374 Stem Cell Reports j Vol. 8 j 373–386 j February 14, 2017lated the expression of the late OB maturation markers
bone gamma-carboxyglutamate protein (BGLAP) and in-
tegrin binding sialoprotein (IBSP) (Figure 2E). Moreover,
LGMN knockdown enhanced the formation of mineralized
ECM, as shown by the increased extent and intensity of
alizarin red staining (Figure 2F). In contrast, LGMN knock-
down inhibited AD differentiation (Figures 2G and 2H) and
reduced expression of the AD maker genes: peroxisome
proliferator-activated receptor gamma 2 (PPARG2), fatty
acid binding protein 4 (FABP4) and adiponectin, C1Q
and collagen domain containing (ADIPOQ) (Figure 2I) un-
der adipogenic culture conditions. To determine whether
LGMN knockdown stimulated OB differentiation and
bone-forming capacity in vivo, shLGMN or shCtrl cells
were mixed with hydroxyapatite/tricalcium phosphate
granules as an osteoconductive carrier, and implanted sub-
cutaneously in immune-deficient mice. Histological anal-
ysis of the implants after 8 weeks revealed a significant
2-fold increase in the amount of heterotopic bone formed
by the shLGMN compared with the control (shCtrl) cells
(Figures 2J and 2K). Human-specific vimentin staining
showed that the heterotopic bone was generated by the
transplanted hBMSCs (Figure 2L).
Pharmacological Inhibition of Legumain Activity
Enhances OB Differentiation and Impairs AD
Differentiation of hBMSCs
To determine whether legumain proteolytic activity is
required for its effects on hBMSCs differentiation, we em-
ployed a small-molecule legumain inhibitor (SD-134) (Lee
and Bogyo, 2012). hBMSC cultures incubated for 24 hr
with SD-134 (50–500 nM) exhibited significant legumain
inhibition (Figure S1B), but no effect on cell number was
observed during 12 days treatment (Figure S1C). During
in vitro OB differentiation of hBMSCs, SD-134 (50 nM)
treatment did not induce significant changes in ALP activ-
ity (Figure S1D), but enhanced formation of mineralized
matrix (Figure S1E). In contrast, SD-134 treatment in-
hibited AD differentiation (Figures S1F and S1G).
Overexpression of LGMN Impairs OB Maturation and
Enhances AD Differentiation of hBMSCs
To determine whether increased LGMN activity actively
blocks OB differentiation, we employed a retroviral
transduction system to establish hBMSCs stably overex-
pressing full-length LGMN (hBMSC-LGMN) or an empty
vector control (hBMSC-EV). LGMN overexpression was
confirmed by mRNA, protein, and activity measurements
(Figures 3A–3C). The levels of fully processed and acti-
vated legumain protein (36 kDa) were increased in lysates
from hBMSC-LGMN cells (Figures 3B and 3C). In addition,
secreted prolegumain (56 kDa) was detected in the condi-
tioned media from hBMSC-LGMN cells (Figures 3D and
Figure 1. Regulation of Legumain Expression during In Vitro and In Vivo Differentiation of Human Bone Marrow Stromal Cells
(A and B) Immunohistochemical (A) and RNA in situ hybridization (B) analysis of legumain expression and localization in normal human
iliac crest bone biopsies. n = 11 donors. Scale bar, 50 mm. Red arrows, canopy cells; black arrows, reversal cells; arrow heads, osteoclasts; v,
vessel.
(C) qRT-PCR analysis of LGMN expression during osteoblast (OB) differentiation of hBMSCs at 6, 12, and 18 days (D6–D18) after start of
differentiation (day 0, D0). Data represent mean ± SD from three independent experiments. *p% 0.05, **p% 0.01, two-tailed unpaired
Student’s t test.
(D) Western blot analysis of legumain expression in cell lysates from hBMSC cultures during OB differentiation.
(E) Quantification of the mature legumain (36 kDa) band intensity. Arbitrary units (ARBU). Data represent mean ± SD from three
independent experiments. *p% 0.05, **p% 0.01, two-tailed unpaired Student’s t test.
(F) Quantification of legumain activity in cell lysates from hBMSCs during OB differentiation. Data represent mean ± SD from three
independent experiments. *p% 0.05, two-tailed unpaired Student’s t test.
(G) qRT-PCR analysis of LGMN expression during adipocyte (AD) differentiation of hBMSCs. Data represent mean ± SD from three inde-
pendent experiments. **p% 0.01, two-tailed unpaired Student’s t test.
(H) Western blot analysis of legumain expression in cell lysates from hBMSC cultures during AD differentiation.
(I) Quantification of the mature legumain (36 kDa) band intensity. Data represent mean ± SD from three independent experiments.
*p% 0.05, two-tailed unpaired Student’s t test.
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Figure 2. Legumain Knockdown Enhanced Osteoblast Differentiation and In Vivo Bone Formation and Inhibited Adipocyte Dif-
ferentiation of Human Bone Marrow Stromal Cells
hBMSCs were stably transfected with control (shCtrl) or LGMN shRNA (shLGMN).
(A) qRT-PCR analysis of LGMN expression. Data represent mean ± SD from three independent experiments. *p% 0.05, two-tailed unpaired
Student’s t test.
(B) Western blot analysis of legumain and GAPDH control. Data represent three independent experiments.
(C) Quantification of legumain activity. Data represent mean ± SD from three independent experiments. **p% 0.01, two-tailed unpaired
Student’s t test.
(D) Quantification of alkaline phosphatase (ALP) activity in the presence of standard culture medium (SCM) or osteoblast induction
medium (OIM) (day 6). Data represent mean ± SD from three independent experiments. p > 0.05, two-tailed unpaired Student’s t test.
(E) qRT-PCR gene expression analysis of the early (ALP, Col1a1) and late (BGLAP, IBSP) OB marker genes. Data represent mean ± SD from
three independent experiments. *p% 0.05, **p% 0.01, two-tailed unpaired Student’s t test.
(F) Quantification of alizarin red staining at day 12. Data represent mean ± SD from three independent experiments. *p% 0.05, two-tailed
unpaired Student’s t test.
(G and H) Quantification of accumulated lipid droplets in the presence of AD induction medium using oil red O staining (day 12). Scale bar,
150 mm, Data represent mean ± SD from three independent experiments. *p% 0.05, two-tailed unpaired Student’s t test.
(I) qRT-PCR gene expression analysis of the AD marker genes PPARG2, FABP4, LPL, and ADIPOQ. Data represent mean ± SD from three
independent experiments. *p% 0.05, two-tailed unpaired Student’s t test.
(J) Histological analysis of in vivo bone formation by hBMSCs stably transfected with non-targeting control shRNA (shCtrl) or LGMN shRNA
(shLGMN), 8 weeks after implantation in immune-deficient mice. Arrows, hydroxyapatite; arrow heads, bone. Scale bars: top panels,
500 mm; bottom panels, 250 mm.
(legend continued on next page)
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3E). In contrast to LGMN knockdown, hBMSC-LGMN
exhibited increased cell proliferation (Figure S1H),
impaired OB maturation, demonstrated by decreased late
OB marker gene expression (BGLAP, IBSP), and decreased
mineralized matrix formation, whereas expression of early
OB commitment markers (ALP, Col1a1) was not altered by
LGMN overexpression (Figures 3F and 3G). hBMSC-LGMN
cells also exhibited enhanced AD differentiation (Figures
3H and 3I), and enhanced expression of AD marker genes
(PPARG2, FABP4, and ADIPOQ) (Figure 3J). Thus, increased
LGMN activity biases hBMSC differentiation to non-OB
fates.
Legumain Degrades Fibronectin during hBMSC
Differentiation
Since ECM proteins play an important role in OB differen-
tiation (Hoshiba et al., 2012) and fibronectin functions as a
master organizer of ECM biogenesis (Halper and Kjaer,
2014), we tested whether the effect of legumain on hBMSC
differentiation is mediated through regulation of fibro-
nectin levels. Lysates from legumain-deficient and legu-
main-overexpressing cells during in vitro OB differentia-
tion showed an inverse relationship between the protein
levels ofmature legumain (36 kDa) and fibronectin (Figures
4A–4F). FibronectinmRNA (FN1) levels did not change dur-
ing OB differentiation (Figure S2A), which is consistent
with post-transcriptional regulation. Incubation of purified
human fibronctin with lysates from legumain-overexpress-
ing HEK293 cells (Smith et al., 2012) confirmed that fibro-
nectin is degraded by a legumain-dependent process in a
dose- and time-dependent manner (Figure S2B). The fibro-
nectin-degrading activity was also present in lysates from
LGMN-overexpressing hBMSCs (Figure 4G). To determine
whether intact fibronectin is required for OB differentia-
tion, we blocked FN1 expression using siRNA, which
inhibitedOBmaturation and formation ofmineralizedma-
trix (Figure 4H). To determine whether fibronectin degra-
dation is sufficient to explain the inhibitory effects of legu-
main on OB maturation, we exposed osteogenic hBMSC
cultures to a panel of purified ECM proteins (gelatin,
collagen type 1, and fibronectin). Both gelatin and fibro-
nectin enhanced the formation of mineralized matrix by
control hBMSC (Figure 4I). However, only fibronectin
blocked the inhibitory effect of legumain on OB differenti-
ation and function (Figure 4J), suggesting that fibronectin
is an endogenous legumain target.(K) Quantification of the heterotopic bone formation, n = 4 implants
Whitney test.
(L) Human-specific vimentin staining of shLGMN implants. Arrows, h
bottom panels, 250 mm. ab, antibody.
See also Figure S1.Legumain-Deficient Zebrafish Exhibit Precocious OB
Differentiation and Bone Mineralization
To examine the function of legumain during bone develop-
ment, we targeted the essential peptidase domain within
the zebrafish lgmn locus using transcription activator-like
effector nucleases (TALENs) (Figure 5A). High-resolution
melt analysis (HMRA) indicated that the lgmn gene was
extensively modified in lgmn-TALEN-injected animals (Fig-
ure 5B). To quantify the extent of lgmn disruption, we used
ON/OUT qPCR (Shah et al., 2015) and determined that
84% of lgmn alleles were modified. We proceeded to
analyze OB differentiation and function in the lgmn-
TALEN-injected animals compared with non-targeted con-
trol-injected animals. At 5 days post-fertilization (dpf)
lgmn-deficient animals exhibited increased expression of
genes associated with OB differentiation, including alka-
line phosphatase (alp) and osteopontin (spp1), while the
expression of the adipogenic marker PPAR-gamma (pparg)
was unchanged (Figure 5C). By 7 dpf lgmn-deficient
zebrafish did not show any gross morphological defects
(Figure 5D). However, there were approximately twice
as many mineralized vertebrae in lgmn-TALEN-injected an-
imals compared with controls (Figures 5E and 5F). Next, we
tested whether post-embryonic OB progenitors remained
sensitive to legumain activity. Zebrafish embryogenesis is
complete by 3 dpf (Kimmel et al., 1995). Therefore, we
treated animals from 3 to 7 dpf with the legumain inhibitor
SD-134. Consistent with the osteogenic effect of genetic
lgmn disruption, SD-134-treated zebrafish exhibited an in-
crease in the number of mineralized vertebrae at 7 dpf
(Figure 5G).
Legumain Serum Levels Decrease with Aging, and
Local Expression of Legumain Is Increased in the Bone
Microenvironment of Osteoporotic Patients
Legumain has recently been identified as a biomarker for
diverse pathological states (Ashley et al., 2016; Guo et al.,
2013; Lin et al., 2014; Lunde et al., 2016; Wang et al.,
2012; Wu et al., 2014). We examined serum levels of legu-
main in 89 women aged 48–87 years and found an inverse
relationship between serum legumain levels and age (Fig-
ure 6A). To determine legumain-localized activity within
the bone microenvironment, we established primary
hBMSC cultures from iliac crest bone marrow aspirates. Le-
gumain levels were significantly higher in osteoporotic
patients compared with age-matched controls (Figures 6Bfor each cell type, Data represent mean ± SEM. *p% 0.05, Mann-
ydroxyapatite; arrow heads, bone. Scale bars: top panels, 500 mm;
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Figure 3. Legumain Overexpression Inhibited Osteoblast and Enhanced Adipocyte Differentiation of Human Bone Marrow Stromal
Cells
See also Figure S1.
(A–C) Legumain (LGMN)-transduced hBMSCs was established using a retroviral transduction system and the successful overexpression of
legumain was confirmed using (A) qRT-PCR analysis of LGMNmRNA expression, (B) western blot analysis of legumain in cell lysate, and (C)
quantification of legumain activity. Data represent mean ± SD from three independent experiments. **p % 0.01, two-tailed unpaired
Student’s t test.
(D–G) Secretion of legumain in the conditioned medium (CM) was evaluated using (D) ELISA measurement (data represent mean from three
technical replicates) and (E) western blot analysis of legumain in the CM from hBMSC-LGMN-overexpressing cell line (LGMN-CM) (data
represent three independent experiments). To assess the effects of legumain on OB differentiation, control hBMSCs containing empty
vector (E.V.) and hBMSC-LGMN cell lines were cultured in OB induction medium, and expressions of OB marker genes were analyzed using
qRT-PCR (F) and mineralized matrix formation was determined by quantification of eluted alizarin red staining (G). Data represent mean ±
SD from three independent experiments. *p% 0.05, **p% 0.01, two-tailed unpaired Student’s t test.
(H and I) To assess the effect of legumain on AD differentiation, control hBMSCs and hBMSC-LGMN cell lines were cultured in AD induction
medium, and (H), (I) accumulation of lipid droplets was measured by quantification of the eluted oil red O staining, *p% 0.05, two-tailed
unpaired Student’s t test. Scale bar, 150 mm.
(J) Expressions of AD marker genes were measured by qRT-PCR (day 7). Data represent mean ± SD from three independent experiments.
*p% 0.05, two-tailed unpaired Student’s t test. E.V., empty vector; LGMN, legumain-overexpressing hBMSCs.and 6C). In addition, immunohistochemical analyses of
bone biopsies from postmenopausal osteoporotic patients
(n = 13) and age-matched controls (n = 11) revealed legu-378 Stem Cell Reports j Vol. 8 j 373–386 j February 14, 2017main overexpression in bonemarrowADs inmost osteopo-
rotic samples (8 out of 13) (Figure 6D). To determine
whether legumain-overexpressing ADs affected adjacent
Figure 4. Legumain Degrades Fibronectin in Human Bone Marrow Stromal Cell cultures
(A) Western blot analysis of legumain and fibronectin in cell lysates of hBMSC lines with stable knockdown of legumain (shLGMN) during
ex vivo OB differentiation (day 0–7).
(B and C) Quantification of protein band intensities in (A). *p% 0.05, **p% 0.01, two-tailed unpaired Student’s t test.
(D) Western blot analysis of legumain and fibronectin in cell lysates of hBMSC lines with stable overexpression of legumain (LGMN) during
ex vivo OB differentiation (day 0–7).
(E and F) Quantification of protein band intensities in (D). Data represent mean ± SD from three independent experiments. *p% 0.05,
**p% 0.01, two-tailed unpaired Student’s t test.
(G) Western blot analysis of human fibronectin degradation by purified legumain from bovine kidneys (bLeg; 10:1 w/w; control) and the
cell lysates from hBMSCs stably transfected with E.V. or legumain (LGMN; legumain overexpression).
(H) Quantitation of mineralized matrix formation on day 15 of OB differentiation, in the presence of siRNA against fibronectin (siFN) and
non-targeting control siRNA (siCtrl). Data represent mean ± SD from three independent experiments. **p% 0.01, two-tailed unpaired
Student’s t test.
(I and J) Effect of different ECM proteins (gelatin, collagen 1, or fibronectin) on mineralized matrix formation by hBMSCs visualized
by alizarin red staining and quantification. Data represent mean ± SD from three independent experiments. *p % 0.05, **p % 0.01,
two-tailed unpaired Student’s t test.
See also Figure S2.
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Figure 5. Legumain Inhibits OB Differentiation and Bone Mineralization In Vivo
(A) Conservation of zebrafish lgmn. I, amino acid identity; S, amino acid similarity.
(B) High-resolution melting analysis of pooled lgmn-TALEN and control-injected animals at 3 days post-fertilization (dpf).
(C) qRT-PCR analysis of OB and AD marker genes at 5 dpf. Data represent mean ± SEM of three pools of ten animals. *p% 0.05, two-tailed
unpaired Student’s t test.
(D and E) Control and lgmnmutant animals at 7 dpf. Scale bars, 500 mM. (D) Bright field and (E) fluorescent alizarin red staining. (E0 and E00)
Higher-magnification images of boxed regions. Arrowheads, whole vertebrae stained; arrows, partial vertebrae stained. Scale bars, 100 mM.
(F) Number of alizarin-red-stained vertebrae in lgmn and control animals at 7 dpf. Data represent mean ± SEM, n > 30 for each group.
*p% 0.05, ***p% 0.005 two-tailed unpaired Student’s t test.
(G) Animals were treated with SD-134 (500 mM) or 1% DMSO from 3 to 7 dpf. Number of alizarin-red-stained vertebrae at 7 dpf. Data
represent mean ± SEM, n = 12 for each group. ***p% 0.005 two-tailed unpaired Student’s t test.bone formation, we measured the trabecular bone volume
in 80 random regions of interest (ROI = 1mm2) in osteopo-
rotic bone biopsies. Regions with legumain-positive ADs
exhibited significantly reduced trabecular bone volume
and there was an inverse relationship between legumain
immunoreactivity in ADs and the local trabecular bone vol-
ume (Spearman r = 0.314, p = 0.004) (Figure 6E).DISCUSSION
Our findings demonstrate a physiological role of legumain
in regulating bone formation and possibly bone mass, as
well as a role in the pathophysiology of reduced bone380 Stem Cell Reports j Vol. 8 j 373–386 j February 14, 2017mass observed in patients with postmenopausal osteopo-
rosis. In particular, we find that legumain functions in
the bone-remodeling microenvironment to inhibit OB dif-
ferentiation and to enhance AD differentiation of hBMSCs,
through regulation of ECM fibronectin deposition.
Our studies demonstrate that legumain inhibits late
stages of ex vivo OB differentiation and the formation of
mineralized ECM, suggesting that legumain regulates the
ECM-hBMSC interaction that is required for the expression
of the mature OB phenotype (Mathews et al., 2012). We
identified fibronectin degradation as a mediator of legu-
main effects, similar to its role in renal proximal tubular
cells, which is required for normal renal function (Morita
et al., 2007). Fibronectin is known to enhance OB
Figure 6. Effect of Aging and Osteoporosis on Legumain Protein Levels in Human Serum and Bone Microenvironment
(A) Serum legumain levels in 89 women, aged 48–87 years, p < 0.0001 using Spearman correlation analysis.
(B) Western blot analysis of mature legumain (36 kDa) and GAPDH in cell lysates from primary hBMSC cultures established from bone
marrow aspirates of osteoporotic patients (n = 5) and age-matched controls (n = 3).
(C) Quantification of western blot band intensities normalized to GAPDH. Data represent mean ± SD from three independent experiments.
***p% 0.005, two-tailed unpaired Student’s t test.
(D) Upper panel: legumain staining of bone biopsies from postmenopausal osteoporotic patients (n = 11) and age-matched control in-
dividuals (n = 13). Scale bars, 1 mm. Lower panel: higher-magnification images of the boxed regions. Scale bars, 50 mm.
(E) Correlation of trabecular bone area with legumain expression by adipocytes in biopsies from postmenopausal osteoporotic patients
(n = 80 random regions of interest [ROI] = 1 mm2), p = 0.004 using Spearman correlation analysis.
(F) Proposed mode-of-action of legumain for regulation of hBMSC lineage commitment.
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differentiation through interaction with the a5b1 integrin
receptor and is required for OB maturation, survival, and
matrix mineralization (Brunner et al., 2011; Linsley et al.,
2013; Mathews et al., 2012; Moursi et al., 1997). In
contrast, fibronectin exerts inhibitory effects on lipid accu-
mulation and AD differentiation (Antras et al., 1989; Rodri-
guez Fernandez and Ben-Ze’ev, 1989; Spiegelman and
Ginty, 1983).
Our data suggest that the proteolytic activity of legumain
is important for its effects on hBMSC differentiation and
bone formation. Legumain has been reported to regulate
bone resorption through inhibition of osteoclast formation
and function by its C-terminal fragment (17 kDa), which is
enzymatically inactive, suggesting that legumain exerts
protease-independent functions (Choi et al., 1999). In
addition, legumain exhibits carboxypeptidase (Dall and
Brandstetter, 2013) and peptide ligase activity (Dall et al.,
2015). The possible involvement of these actions of legu-
main in regulating skeletal homeostasis requires further
studies.
We observed that genetic loss- and gain-of-function of le-
gumain were associated with changes in BMSC prolifera-
tion. However, regulation of BMSC proliferation by legu-
main is independent of its enzymatic activity, since
small-molecule inhibition of legumain activity did not
alter BMSC proliferation. This observation corroborates
previous reports showing regulation of cell proliferation
by legumain, independent of its enzymatic activity (An-
drade et al., 2011). Further support of the potential role
of legumain in osteoprogenitor cell proliferation is based
on its colocalization with the proliferating osteoblastic
cells in human bone biopsies. The proliferation status of
osteoprogenitor cells near the bone-forming surfaces, as
determined by immunohistochemical analysis of Ki-67,
has been previously reported in human bone specimens
(Kristensen et al., 2014). Interestingly, the pattern of Ki-
67 immunoreactivity coincided with legumain expression,
as the legumain-positive osteoprogenitor cells (such as can-
opy cells) are also Ki-67 positive, whereas the mature oste-
oblastic cells (such as bone-lining cells) are both legumain
negative and Ki-67 negative.
We employed the zebrafish model to investigate the
developmental and pharmacological effects of legumain
inhibition in vivo. Zebrafish is an attractive model for
in vivo screening studies, due to the molecular and cellular
conservation of skeletal development and its predictive
value when studying human diseases (Fisher et al., 2003;
Grimes et al., 2016; Hayes et al., 2014; Li et al., 2009). For
example, mutations in zebrafish collagen type IA1 repro-
duce many aspects of osteogenesis imperfecta (Fisher
et al., 2003), and ptk7 mutant zebrafish have been identi-
fied as suitable models for scoliosis (Grimes et al., 2016).
We extend the usefulness of this model by showing that382 Stem Cell Reports j Vol. 8 j 373–386 j February 14, 2017late developmental events such as the mineralization of
vertebrae are amenable to analysis in TALEN-injected ani-
mals. Our finding that legumain-deficient zebrafish exhibit
enhanced OB differentiation and bone mineralization is
consistent with the in vitro effects of legumain knock-
down. In addition, we show that post-embryonic pharma-
cological inhibition of legumain recapitulates the osteo-
genic effects of genetic legumain ablation.
The serum levels of legumain decreased with aging,
which was counterintuitive in relation to the proposed
function of legumain in bone. However, the major tissue
source(s) of serum legumain are not known and the
decline in serum levels of legumain with aging may be
connected to age-related decrease in renal function that
may influence both clearance and production of legumain
(the kidneys could be a major source of circulating legu-
main, but this is not clear at the moment). Thus, direct ex-
amination of legumain within the bone microenviron-
ment is required for understanding its biological role in
skeletal homeostasis.
Osteoporosis is a systemic bone disease, characterized
by decreased bone formation, reduced bone mass, and
disruption of normal bone architecture, resulting in
bone fragility and increased risk of fractures (Compston,
2010). Legumain expression was elevated in hBMSCs
from osteoporotic patients and, at single-cell resolution,
legumain overexpression in ADs inversely correlated
with local trabecular bone volume. Bioinformatic analysis
revealed the presence of NF-kB binding sites in the legu-
main promoter, suggesting that the proinflammatory cy-
tokines (e.g., TNF-a and IL6), known to be upregulated
in osteoporotic bone marrow microenvironment (Char-
atcharoenwitthaya et al., 2007), could regulate legumain
expression.
In summary, our findings identified legumain as a ‘‘mo-
lecular switch’’ with opposing effects on bone and fat
formation by hBMSCs through degradation of the ECM
protein fibronectin (Figure 6F) and that altered expression
of legumain in the bone microenvironment contributes
to the pathophysiology of trabecular bone loss in osteopo-
rosis. Finally, our data suggest that inhibition of legumain
activity would be a promising approach to enhance bone
regeneration.EXPERIMENTAL PROCEDURES
Cell Culturing, Differentiation, and siRNA
Transfection
We have employed our well-characterized hBMSC-TERT cell line
(as amodel of hBMSC) established by ectopic expression of the cat-
alytic subunit of human telomerase, as described previously (Ab-
dallah et al., 2005; Simonsen et al., 2002). Primary hBMSC cultures
were established from bone marrow aspirates of osteoporotic
patients and age-matched control subjects, as described before (Lee
et al., 2004). Informed consent was obtained from all donors and
the study was approved by the Scientific Ethics Committee of
the Region of Southern Denmark (issue no. 2003-41-3206, 2008-
00-92). Cells were cultured in standard culture medium (SCM)
containingminimal essential medium (MEM) (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (P/S) (Gibco) at 37C in a humidified atmosphere
containing 5% CO2. All employed cell types were regularly tested
for mycoplasma contamination.
Cell culture plates were coated with collagen type 1 (6 mg/cm2;
Sigma), gelatin (1 mg/cm2; Sigma), or fibronectin (1 mg/cm2; Sigma)
and incubated at room temperature for 1 hr. The solutionwas then
removed and the plates were air dried for 45 min, rinsed with PBS
(without Ca2+ or Mg2+) followed by seeding cells.
For OB differentiation, 20 3 103 cells/cm2 were seeded and
induced with OB induction medium (OIM) containing 10 mM
b-glycerophosphate (Calbiochem), 10 nM dexamethasone
(Sigma), 50 mg/ml L-ascorbic acid (Wako Pure Chemicals Indus-
tries), 10 nM 1,25-dihydroxyvitamin D3 (LEO Pharma) in MEM
supplemented with 10% FBS and 1% P/S. The medium was
changed every third day. Control cells were cultured in SCM.
Quantification of ALP activity and alizarin red staining were per-
formed as described previously (Jafari et al., 2015).
For AD differentiation, cells were plated at a density of 35 3
103 cells/cm2 and induced with adipogenic induction medium
containing 10% horse serum (Gibco), 100 nM dexamethasone
(Sigma), 500 nM insulin (Sigma), 1 mM BRL49653 (Sigma),
and 0.25 mM 3-isobutyl-1-methylxanthine (Sigma) in MEM
medium supplemented with 10% FBS and 1% P/S. The medium
was changed every third day. Control cells were cultured in
SCM. Oil red O staining of the accumulated lipid droplets
in mature ADs was performed as described previously (Jafari
et al., 2015).
Small interfering RNA (siRNA) transfection was carried out as
described previously (Jafari et al., 2015). In brief, Lipofectamine
2000wasusedas transfection reagentanda reverse-transfectionpro-
tocol was employed according to the manufacturer’s instructions
(Invitrogen) and OB differentiation was induced 48 hr after
siRNA transfection.Non-targetingno. 1 siRNA (Ambion) and siRNA
against fibronectin (sense: GGCUCAGCAAAUGGUUCAGtt) (Am-
bion) were used at 25 nM (Hammond and Kruger, 1988) (Schuck
et al., 2004).Legumain Activity Assay
Cells were washed with PBS and lysed using lysis buffer containing
1 mM disodium EDTA, 100 mM sodium citrate, 1% n-octyl-b-D-
glucopyranoside (pH 5.8). The total protein concentration in the
lysates was measured using Bradford assay (Hammond and Kruger,
1988). To measure legumain activity, 10 mg total protein in a total
volumeof 20 mLwas added to 100 mL of assay buffer (39.5mMcitric
acid, 121 mM Na2HPO4, 1 mM Na2EDTA, 0.1% 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate, and 1 mM DTT)
in a dark 96-well plate, followed by adding 50 mL of peptide sub-
strate (Z-Ala-Ala-Asn-AMC; 10 mM final concentration) (Bachem)
in assay buffer as described previously (Johansen et al., 1999).
The plate was then incubated at 30C for 1 hr and the fluorescentintensity (380EX/460EM) was measured using a FLUOstar Omega
multimode microplate reader.Heterotopic Bone Formation Assay In Vivo
To evaluate the in vivo bone formation, 5 3 105 cells of either
shLGMN or shCtrl cell lines were loaded on scaffolds containing
40 mg hydroxyapatite/tricalcium phosphate ceramic powder
(Zimmer Scandinavia), incubated at 37C overnight, and im-
planted subcutaneously on the dorsal side of 8-week-old female
non-obese diabetic.CB17-Prkdcscid/J mice as described previously
(Abdallah et al., 2008). A simple randomization method was used
to assign mice to different groups. After 8 weeks, implants (n = 4
implants/cell line) were retrieved and fixed in 4% formaldehyde
for 24 hr, decalcified in formic acid for 3 days, and embedded in
paraffin. sections (4 mm, n = 9/implant) were cut and stained
with H&E(Bie & Berntsen). Bone volume per total volume was
blindly quantified using pixel scoring method as described previ-
ously (Abdallah et al., 2008). Human-specific vimentin staining
(Thermo Scientific, RM-9120) was used to show that the bone
formed in the implants was of human origin. Mice experiments
were carried out in accordance with permissions issued by the
Danish Animal Experiments Inspectorate (2012-DY-2934-00006).Zebrafish Studies
Zebrafish (Danio rerio) were housed at 28C, in a 14 hr light and
10 hr dark cycle. Embryos were collected by natural spawning
and raised at 28C in E3 solution according to standard protocols
(Westerfield, 2007). A pair of TALENs recognizing exon 4 of the ze-
brafish lgmn gene were constructed by the platinum gate method
(Sakuma et al., 2013). lgmn_TAL1: NN-NG-NN-NG-NG-NG-NI-
NN-NG-NI-NI-HD-HD-HD-NG-NI-HD. lgmn_TAL2: HD-HD-NI-
NG-NG-NG-NN-NN-NG-HD-NG-NN-NG-NG. TALEN mRNA was
synthesized by in vitro transcription using the T7 mMESSAGE
mMACHINE Kit (Ambion). mRNA (125 pg) encoding each TALEN
heterodimer was injected into the cytoplasm of the cell of one-cell-
stage wild-type zebrafish embryos. Control injections used
lgmn_TAL1 and an irrelevant TAL2. TALEN efficiency was moni-
tored by HRMA using KAPA-HRM master mix (Kapa Biosystems)
on an Eco Real-Time PCR machine (Illumina). HRMA_F: 50-TGA
TTT GTC AGT TCT TGC TCC TT-30. HRMA_R: 50-ACT TAC GTC
CCC AAT GTA GTC C-30. ON/OUT PCR was performed as
described using HRMA_F + HRMA_R as outer primers and
HRMA_F + lgmn_ON: 50-CCA TTT GGT CTG TTT ATG ACC ACT-
30 for ‘‘ON’’ PCR (Shah et al., 2015). Total RNA was extracted
from cultured cells using TRIzol reagent (Invitrogen) and the
aqueous phase was isolated by column purification (Zymo
Research). qRT-PCRwas performed using a KAPAOne-Step Univer-
sal Master Mix (KAPA Biosystems) on an Eco Real-Time PCR ma-
chine (Illumina) using the DDCT method. Table S3 shows the
primers used for qRT-PCR. Alizarin red staining and blind quanti-
fications of the vertebrae were performed as described previously
(Westerfield, 2007) and imaged with a Leica M165 FC microscope.
SD-134 was added to E3medium at 500 mM in 1%DMSO from 3 to
7 dpf. Simple randomization was used to assign the fish to SD-134
or DMSO groups. The use and treatment of zebrafish in this project
were in accordance with and approved by the Animal Ethics Re-
view Committee, Garvan Institute of Medical Research.Stem Cell Reports j Vol. 8 j 373–386 j February 14, 2017 383
Immunohistochemical Analyses of Human Bone
Specimens
Bone biopsy specimens from 13 postmenopausal osteoporotic pa-
tients (mean age, 77 years; range, 68–86 years) and 11 age-matched
controls (mean age, 75 years; range, 67–83 years) were included in
the study (Kristensen et al., 2014). In accordance with approval
from theDanishNationalCommitteeonBiomedical Research Ethics
(journal no S-2007.01.21), formal consent was not required for the
controls, whose biopsies were included in the study retrospectively;
oral and written informed content was obtained from the osteopo-
rotic donors included in the study. Sections (3.5-mm thick) from the
decalcified paraffin-embedded bone specimens from postmeno-
pausal osteoporotic patients and controls were immunostained
with mouse anti-legumain (1:400, Santa Cruz, SC-133234, clone
B-8) antibodies, which were labeled with peroxidase-conjugated
anti-mouse IgG polymers (1:10; DPVM110HRP, BrightVision).
The signal was amplified with digoxigen-conjugated peroxidase-
reactive tyramide (1:900; NEL748B001KT, Perkin-Elmer), labeled
with alkaline-phosphatase-conjugated sheep anti-digoxigen (1:500;
11093274910, Roche), and visualized with Liquid Permanent Red
(DAKO). The stained sections were counterstained with Mayer’s he-
matoxylin and mounted with Aqua-Mount. The semi-quantitative
analyses estimated the prevalence of cells with either weak (+1),
moderate (+2), or strong (+3) staining within the different cell popu-
lations. We employed systematic random analysis for selection of
visual fields following the central axis in the biopsies. The H score
(range, 0–300) was calculated using the previously published equa-
tion (Andersen et al., 2013; Detre et al., 1995). H score =
P
Pi 3 i,
where i is the staining intensity (0–3) and Pi is the percentage of cells
stained with each intensity (0%–100%).
Statistical Analysis
Statistical analyses were performed using Prism 6.0 (GraphPad) or
Microsoft Excel 2010. Data are represented as mean ± SD of at least
three independent experiments, unless otherwise stated. Normal
distribution of the data was tested using the D’Agostino-Pearson
omnibus normality test. Testing for statistical differences between
variables was carried out using two-tailed unpaired Student’s t test
on the normally distributed data. Statistical differences between
variables that did not follow normal distribution were determined
using the Mann-Whitney test. Linear regression analysis and the
Spearman correlation coefficient (r) were employed for the correla-
tion analyses. p% 0.05 was considered statistically significant.
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